Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
08.02.2017 22:59:00

Bernstein Liebhard LLP Investigates Claims On Behalf Of Shareholders Of Teva Pharmaceuticals Industries, Ltd.

NEW YORK, Feb. 8, 2017 /PRNewswire-USNewswire/ -- Bernstein Liebhard LLP is investigating whether the Board of Directors of Teva Pharmaceuticals Industries, Ltd. ("Teva" or the "Company") (NYSE: TEVA) breached their fiduciary duties to the Company's shareholders.

On February 7, 2017, amid reports of a bribery investigation, Teva announced that its Chief Executive Officer Erez Vigodman will resign. Teva shares fell approximately 6% on this adverse news.

If you are interested in discussing your rights as a Teva shareholder, and/or have information relating to the matter, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or seidman@bernlieb.com.

Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3.5 billion for its clients. The Firm has been named to the National Law Journal's "Plaintiffs' Hot List" thirteen times. 

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414
www.bernlieb.com

ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information
Joseph R. Seidman, Jr.
Bernstein Liebhard LLP
http://www.bernlieb.com
(212) 779-1414
seidman@bernlieb.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bernstein-liebhard-llp-investigates-claims-on-behalf-of-shareholders-of-teva-pharmaceuticals-industries-ltd-300404607.html

SOURCE Bernstein Liebhard LLP

Analysen zu Teva Pharmaceutical Industries Ltd. (spons. ADRs)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel